Skip to search formSkip to main contentSkip to account menu

emtansine

Known as: DM1 compound 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Maytansine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Characterization of T‐DM1‐resistant breast cancer cells
The development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T‐DM1… 
Review
2016
Review
2016
ErbB2: From an EGFR Relative to a Central Target for Cancer Therapy.
See related article by Berger et al., [Cancer Res 1988;48:1238–43][1] . Visit the Cancer Research 75th Anniversary [timeline][2… 
Review
2016
Review
2016
Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
Since the approval of trastuzumab, a humanized monoclonal antibody against the extracellular domain of human epidermal growth… 
Review
2015
Review
2015
Treatment of HER 2-positive Breast Cancer
The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or amplified in ~ 15% of breast cancer patients and… 
2014
2014
Enhanced anticancer activity of DM1-loaded star-shaped folate-core PLA-TPGS nanoparticles
The efficient delivery of therapeutic drugs into interested cells is a critical challenge to broad application of nonviral vector… 
2014
2014
Télangiectasies cutanéo-muqueuses diffuses induites par l’anticorps conjugué TDM-1
2014
2014
From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.
145 ISSN 1479-6694 10.2217/FON.13.252 © 2014 Future Medicine Ltd Future Oncol. (2014) 10(2), 145–148 Almost six decades have been… 
2013
2013
Fifteen years of anti-HER2 therapy.
Last month brought the accelerated approval by the US Food and Drug Administration (FDA) of a fourth agent targeting the human… 
Review
2012
Review
2012
Recent advances in novel targeted therapies for HER2-positive breast cancer
The monoclonal antibody trastuzumab has improved the outcomes of patients with breast cancer that overexpresses the human… 
Highly Cited
2010
Highly Cited
2010
Antibody–drug conjugates for cancer: poised to deliver?
Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)